The effect of inaccuracies in assessing gestational age alone in terms of final management may be estimated. With 60°h concordance nearly 2%, of all women may be subjected to amniocentesis when they do not really need it while in 2% the test may be omitted when it is actually required. Even with 90% concordance (unattainable in practice at present) the false-positive and false-negative rates are still over 1°. Expressing this differently, with an amniocentesis rate of 5 0 0-that is, all mothers with serum AFP concentrations over the 95th centile-and 70%0 accuracy of gestational dating to ± 1 week, 32%h of mothers referred for amniocentesis may not actually need it and only 68% of those who need it will actually have it. The present study was carried out in optimal clinical circumstances and the levels of precision obtained are likely to underestimate rather than overestimate the true extent of the problem.
Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause S CHAKRAVARTI, W P COLLINS, M H THOM, J W W STUDD British Medical_Journal, 1979, 1, 983-985 Summary and conclusions Out of a consecutive series of 300 patients seen at a menopause clinic, 82 complained of symptoms generally associated with the climacteric, although they were still menstruating. Vasomotor disturbances were absent in 42 of these patients (group 1) and present in 40 (group 2). Headaches, insomnia, and dyspareunia were the most common complaints among the women with vasomotor symptoms, whereas loss of libido and depression predominated in those without. Conjugated equine oestrogens (Premarin) 125 mg daily given for three weeks out of four relieved nearly all symptoms in group 2, but in group 1 the response was disappointing.
The mean plasma oestradiol concentration in women with vasomotor symptoms was significantly lower than that observed during days 1-10 of the menstrual cycle, but plasma testosterone values were not significantly different from those observed in younger women. Plasma follicle-stimulating hormone (FSH) and luteinising hormone (LH) concentrations were similar to those seen after the menopause. Concentrations of these hormones in the women without vasomotor symptoms were similar to those in the younger, regularly menstruating women. After six months of oestrogen treatment patients in group 2 had a 2-1-fold increase in mean plasma oestradiol concentration, and plasma FSH and LH concentra- Results Table I gives the age distribution of the 82 women studied, and vasomotor symptoms. Headaches, insomnia, and dyspareunia were the most common complaints among women who were experiencing these vasomotor disturbances, whereas loss of libido and depression were more prevalent in women who were not complaining of hot flushes. Other symptoms were evenly distributed between the two groups. Three patients stopped oestrogen treatment because of nausea and breast discomfort, and four were lost to follow-up. Of the 38 patients in group 2 who completed six months of treatment, all except four obtained relief in the frequency and intensity of symptoms (table II) . There was pronounced relief of nearly all symptoms in this group, whereas in group 1 the response was disappointing. Table III gives the mean plasma hormone concentrations in the two groups before treatment. The plasma oestradiol concentration in women with vasomotor symptoms was significantly lower (P < 0 005) than the values observed during days 1-10 of the menstrual cycle (mean 250-3 pmol/l (68-2 pg/ml), range 90 4-600 8 pmol/l (24 6-164-0 pg/ml)), even though they were still menstruating. The concentration of testosterone, however, did not differ significantly from that in the younger women (mean 1-4 nmol/l (0-4 ng/ml), range 0 6-2 2 nmol/l (0-17-0-63 ng/ml)). These premenopausal women experiencing hot flushes had plasma FSH and LH concentrations comparable to those seen after the menopause (LH: mean 53 8 U/1, range 21 5-80 2 U/1; FSH: mean 48-2 U/1, range 11-2-81 2 U/1). emphasise that the data consist of self-reported symptoms that cannot be independently verified. The design of the study did not allow us to test the reliability of reporting or any placebo response. There was also a problem of suggestion-namely, that an affirmative response might have been given to a listed symptom which, had it not been suggested, might not have been mentioned. This would be likely to lead to overreporting of symptoms. Thus, we do not emphasise the prevalence of symptoms but have attempted to correlate groups of symptoms to hormonal state in order to identify women who would benefit most from oestrogen-replacement therapy. Climacteric symptoms in premenopausal women may not be easy-to diagnose. A particular problem is in differentiating true oestrogen-deficiency symptoms from those due to other factors. In a prospective placebo study, Utian5 concluded that only hot flushes, sweats, atrophic vaginitis, and depression responded convincingly to oestrogen-replacement therapy. Other workers reported a large placebo effect on all of the alleged symptoms of the climacteric,6 10 but a definite benefit of oestrogen treatment was shown in the studies over and above the placebo response. A contemporary danger in difficult cases is the risk of extending the proper indications for oestrogen therapy to patients with affective disorders and personality or domestic problems in a desperate attempt to find treatment. This is particularly a problem in premenopausal patients, in whom the precise diagnosis of oestrogen-deficiency symptoms may not be straightforward.
Our analysis of symptoms shows that the patients who suffered from hot flushes more often complained of headaches, dyspareunia, pains in the muscles and joints, and insomnia, possibly due to night sweats. These complaints may be regarded as related to the climacteric since they noticeably improved with oestrogen treatment and were oestrogen-responsive in Campbell and Whitehead's double-blind placebo study.6 Patients with so-called "menopausal symptoms" but not hot flushes complained of a multiplicity of symptoms, loss of libido and depression predominating, and did not have such a beneficial response to oestrogen. The fourth and fifth decades in a woman's life are often accompanied by distressing psychological changes,"1 12 and the variability in therapeutic response in depressive illness suggests multiple aetiological factors in these cases.
The plasma FSH concentrations in our patients complaining of hot flushes were significantly higher than those observed in the reproductive age group. Our results support the view of Moore et al,12 who suggested that 15 U/I was the upper limit of normal and served as a useful cut-off value in distinguishing true symptoms of oestrogen deficiency in the climacteric. This was not true of plasma LH concentrations, which, although significantly raised in patients with hot flushes responding to oestrogen treatment, never reached the high values of the preovulatory surge in the younger, fertile woman.
Plasma oestradiol concentrations were significantly (P <0005) lower in the premenopausal women with hot flushes than in those without; with oestrogen treatment values increased to normal. Plasma testosterone concentrations remained in the normal premenopausal range in both groups of patients. Oral oestrogen treatment for six months resulted in a two-fold increase in concentrations in both groups. This was probably consequent on an increase in sex-hormone-binding globulin with oestrogen treatment, which results in a higher proportion of bound testosterone in the plasma and is of no biological importance.
FSH and LH concentrations in the plasma declined with oestrogen therapy, but even after six months of continuous treatment the values remained higher than those observed in the proliferative phase of the ovarian cycle.
About a quarter of the women referred to the menopause clinic are premenopausal with symptoms that may respond to oestrogen treatment. Characteristic symptoms, which must include vasomotor disturbances, and the finding of a high plasma FSH concentration are the best criteria on which to select patients for oestrogen-replacement therapy. Some of the remaining patients may respond to oestrogen treatment, but a prospective, double-blind placebo trial is needed to clarify this. Clearly, however, many such patients would benefit from specific psychiatric counselling rather than oestrogen-replacement therapy.
